Status:
RECRUITING
tDCS in Post-Acute COVID-19 Patients With SARDs
Lead Sponsor:
University of Sao Paulo
Conditions:
Rheumatic Diseases
Autoimmune Diseases
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Some patients develop "Post-acute COVID-19 syndrome," in which they experience persistent symptoms after recovering from the acute phase of COVID-19 infection. This syndrome may be more significant in...
Detailed Description
Currently, there are no studies evaluating the tDCS technique in ARD patients with post-acute COVID-19; therefore, the main objective of the present study is to evaluate the safety and efficacy of the...
Eligibility Criteria
Inclusion
- Patients with well-defined ARDs (rheumatoid arthritis, sclerosis systemic, Sjögren syndrome, spondyloarthritis, systemic lupus erythematosus, systemic vasculitis, and systemic autoimmune myopathies)
- Fatigue or general pains.
Exclusion
- Neoplasia, using heart pacemarker, using visceral metalic clips, infections (HIV, HTLV-1, hepatitis), pregnance, previous historical of convulsions or epilepsies
Key Trial Info
Start Date :
May 17 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 4 2024
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04890483
Start Date
May 17 2021
End Date
December 4 2024
Last Update
December 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Samuel K Shinjo
São Paulo, Brazil